文献速递糖尿病

1型糖尿病患者与健康对照者3-羟基丁酸输注的代谢效应:随机交叉试验显示脂肪分解反馈抑制完整

Metabolic effects of 3-hydroxybutyrate infusion in individuals with type 1 diabetes compared with healthy control participants: a randomised crossover trial showing intact feedback suppression of lipolysis.
PubMed 文献 · Diabetologia · 2025-04-10

该单盲随机交叉试验纳入10例1型糖尿病男性和10例健康男性对照,比较静脉输注3-羟基丁酸(3-OHB)与等渗盐水对脂肪分解和葡萄糖代谢的影响。结果显示3-OHB输注在两组均抑制脂肪分解率超过50%,降低循环NEFA约0.5 mmol/L,并降低脂肪组织信号蛋白磷酸化,且两组间相似;葡萄糖代谢指标未受影响。结论提示1型糖尿病患者中3-OHB对脂肪分解的反馈抑制保持完整,3-OHB受体信号异常可能不参与糖尿病酮症酸中毒的发生。

要点

  • 3-OHB输注使1型糖尿病组D/L-3-OHB血浓度升至3.3±0.7 mmol/L,对照组为2.9±0.5 mmol/L(p=0.03)。
  • 3-OHB输注在两组均抑制脂肪分解率超过50%(p<0.001),降低循环NEFA约0.5 mmol/L(p<0.001)。
  • 3-OHB在两组均相似地降低脂肪组织perilipin的PKA磷酸化(p<0.001)及激素敏感性脂肪酶Ser660(p<0.001)和Ser563(p<0.01)磷酸化。

核心结论

  • 在1型糖尿病患者中,3-OHB对脂肪分解、血NEFA浓度及脂肪组织信号活性的抑制作用与健康对照者相比保持完整。
  • 这些发现提示3-OHB受体信号异常可能不参与糖尿病酮症酸中毒的发生。

研究设计与样本

  • 单盲、随机交叉设计,纳入10例诊断为1型糖尿病的男性和10例健康男性对照者。
  • 入选标准为男性、年龄≥18岁、BMI 19-26 kg/m2且无严重合并症/疾病。
  • 过夜空腹后,每位参与者接受两次3小时静脉输注:D/L-3-羟基丁酸钠和等渗盐水(NaCl),两次输注间隔1小时洗脱期。
  • 两种干预的顺序按随机化分配给每位参与者;参与者在整个研究日对分配设盲,但研究者知晓分配的干预顺序。
  • 使用[9,10-3H]棕榈酸和[3-3H]葡萄糖示踪剂评估脂肪分解率和葡萄糖 turnover;通过蛋白质印迹法定量皮下腹部脂肪组织活检中的脂肪组织信号。主要终点指标为棕榈酸通量(脂肪分解率)。

主要发现

  • 输注3-OHB期间,1型糖尿病组D/L-3-OHB血浓度升至3.3±0.7 mmol/L,对照组为2.9±0.5 mmol/L(p=0.03)。
  • 与NaCl相比,3-OHB输注在1型糖尿病组和对照组均有效抑制脂肪分解率超过50%(p<0.001),并降低循环NEFA约0.5 mmol/L(p<0.001)。
  • 在脂肪组织中,3-OHB在1型糖尿病组和对照组均相似地降低perilipin的蛋白激酶A磷酸化(p<0.001)以及激素敏感性脂肪酶Ser660(p<0.001)和Ser563(p<0.01)的磷酸化。
  • 两组的葡萄糖代谢指标在整个研究过程中均未受影响。

临床怎么用

  • 作者认为,3-OHB对脂肪分解的反馈抑制在1型糖尿病中保持完整,提示3-OHB受体信号异常可能不参与糖尿病酮症酸中毒的发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Diabetic ketoacidosis remains a severe complication in type 1 diabetes, arising from insufficient insulin levels and accelerated lipolytic rate, leading to increased β-oxidation of NEFA and ketone body production in the liver. The ketone body 3-hydroxybutyrate (3-OHB) inhibits lipolysis in healthy individuals. The current study aimed to test whether this feedback suppression of lipolysis by 3-OHB is disrupted in individuals with type 1 diabetes. METHODS: We used a single-blind, randomised, crossover design to study ten men diagnosed with type 1 diabetes and ten healthy control participants. Eligibility criteria were male sex, age ≥18 years, BMI of 19-26 kg/m2 and no severe comorbidities/diseases. Following an overnight fast, each participant received two 3 h i.v. infusions: (i) sodium-D/L-3-OHB and (ii) iso-osmolar saline (NaCl), separated by a 1 h washout period. The order of the two interventions was assigned by randomisation for each participant. Participants were blinded to the allocation throughout the study day, but investigators were aware of the assigned intervention order. We evaluated the lipolytic rate and glucose turnover using [9,10-3H]palmitate and [3-3H]glucose tracers. Additionally, adipose tissue signalling was quantified using western blotting techniques in subcutaneous abdominal adipose tissue biopsies. The primary endpoint measure was palmitate flux (lipolytic rate). RESULTS: During the infusion of 3-OHB, the D/L-3-OHB blood concentrations increased to 3.3 ± 0.7 mmol/l in participants with type 1 diabetes compared with 2.9 ± 0.5 mmol/l in control participants (p=0.03). The infusion effectively suppressed the lipolytic rates by more than 50% (p<0.001) and reduced circulating NEFA by approximately 0.5 mmol/l (p<0.001) compared with NaCl in both participants with type 1 diabetes and control participants. In adipose tissue, 3-OHB reduced protein kinase A phosphorylation of perilipin (p<0.001) and hormone-sensitive lipase phosphorylation at Ser660 (p<0.001) and Ser563 (p<0.01) similarly in participants with type 1 diabetes and control participants. Indices of glucose metabolism remained unaffected throughout in both groups. CONCLUSIONS/INTERPRETATION: Our findings indicate that, in individuals with type 1 diabetes, the suppression of lipolysis, blood NEFA concentrations and adipose tissue signalling activity in response to 3-OHB remains intact compared with healthy control participants. These findings imply that derailment of receptor signalling by 3-OHB is unlikely to be involved in the development of diabetic ketoacidosis. TRIAL REGISTRATION: ClinicalTrials.gov NCT04656236 FUNDING: Open access funding provided by Aarhus Universitet. This study was supported by the Novo Nordisk Foundation (NNF19OC0058872) and the Health Research Foundation of Central Denmark Region.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bangshaab M, Svart MV, Rittig N, et al. Metabolic effects of 3-hydroxybutyrate infusion in individuals with type 1 diabetes compared with healthy control participants: a randomised crossover trial showing intact feedback suppression of lipolysis. Diabetologia. 2025. PMID: 40210728. doi:10.1007/s00125-025-06423-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。